Literature DB >> 24717220

Langerhans cell homeostasis and turnover after nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation.

Marco Mielcarek1, Anna Yasmine Kirkorian, Robert C Hackman, Jeremy Price, Barry E Storer, Brent L Wood, Marylene Leboeuf, Milena Bogunovic, Rainer Storb, Yoshihiro Inamoto, Mary E Flowers, Paul J Martin, Matthew Collin, Miriam Merad.   

Abstract

BACKGROUND: Langerhans cells (LCs) are self-renewing epidermal myeloid cells that can migrate and mature into dendritic cells. Recipient LCs that survive cytotoxic therapy given in preparation for allogeneic hematopoietic cell transplantation may prime donor T cells to mediate cutaneous graft-versus-host disease (GVHD). This possible association, however, has not been investigated in the setting of nonmyeloablative allografting.
METHODS: We prospectively studied the kinetics of LC-chimerism after sex-mismatched allogeneic hematopoietic cell transplantation with nonmyeloablative (n=23) or myeloablative (n=25) conditioning. Combined XY-FISH and Langerin-staining was used to assess donor LC-chimerism in skin biopsies obtained on days 28, 56, and 84 after transplant. The degree of donor LC-chimerism was correlated with the development of skin GVHD.
RESULTS: We observed significantly delayed donor LC-engraftment after nonmyeloablative transplantation compared with other hematopoietic compartments and compared with LC-engraftment after myeloablative conditioning. In most recipients of nonmyeloablative transplants, recipient LCs proliferated in situ, recruitment of donor-LCs was delayed by two months, and full donor LC-chimerism was only reached by day 84 after transplant. Although persistence of host LCs on day-28 after transplant was not predictive for acute or chronic skin GVHD, the recruitment of donor-derived LCs was associated with nonspecific inflammatory infiltrates (P=0.009).
CONCLUSIONS: These results show that LCs can self-renew locally but are replaced by circulating precursors even after minimally toxic nonmyeloablative transplant conditioning. Cutaneous inflammation accompanies donor LC-engraftment, but differences in LC conversion-kinetics do not predict clinical or histopathological GVHD.

Entities:  

Mesh:

Year:  2014        PMID: 24717220      PMCID: PMC4149838          DOI: 10.1097/TP.0000000000000097

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  23 in total

1.  Host-derived Langerhans cells persist after MHC-matched allografting independent of donor T cells and critically influence the alloresponses mediated by donor lymphocyte infusions.

Authors:  Nadira Durakovic; Karl B Bezak; Mario Skarica; Vedran Radojcic; Ephraim J Fuchs; George F Murphy; Leo Luznik
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

2.  Fast appearance of donor dendritic cells in human skin: dynamics of skin and blood dendritic cells after allogeneic hematopoietic cell transplantation.

Authors:  Susanne Auffermann-Gretzinger; Lars Eger; Martin Bornhäuser; Knut Schäkel; Uta Oelschlaegel; Markus Schaich; Thomas Illmer; Christian Thiede; Gerhard Ehninger
Journal:  Transplantation       Date:  2006-03-27       Impact factor: 4.939

3.  Self-renewal capacity of human epidermal Langerhans cells: observations made on a composite tissue allograft.

Authors:  Jean Kanitakis; Emmanuel Morelon; Palmina Petruzzo; Lionel Badet; Jean-Michel Dubernard
Journal:  Exp Dermatol       Date:  2010-08-12       Impact factor: 3.960

4.  Langerhans cells arise from monocytes in vivo.

Authors:  Florent Ginhoux; Frank Tacke; Veronique Angeli; Milena Bogunovic; Martine Loubeau; Xu-Ming Dai; E Richard Stanley; Gwendalyn J Randolph; Miriam Merad
Journal:  Nat Immunol       Date:  2006-01-29       Impact factor: 25.606

5.  Langerhans cells are not required for graft-versus-host disease.

Authors:  Hongmei Li; Daniel H Kaplan; Catherine Matte-Martone; Hung Sheng Tan; Srividhya Venkatesan; Kody Johnson; Anthony J Demetris; Jennifer McNiff; Mark J Shlomchik; Warren D Shlomchik
Journal:  Blood       Date:  2010-10-13       Impact factor: 22.113

6.  Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study.

Authors:  R A Nash; R Etzioni; R Storb; T Furlong; T Gooley; C Anasetti; F R Appelbaum; K Doney; P Martin; J Slattery
Journal:  Blood       Date:  1995-06-15       Impact factor: 22.113

7.  Further evidence for the self-reproducing capacity of Langerhans cells in human skin.

Authors:  J M Czernielewski; M Demarchez
Journal:  J Invest Dermatol       Date:  1987-01       Impact factor: 8.551

8.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.

Authors:  R Storb; H J Deeg; J Whitehead; F Appelbaum; P Beatty; W Bensinger; C D Buckner; R Clift; K Doney; V Farewell
Journal:  N Engl J Med       Date:  1986-03-20       Impact factor: 91.245

9.  The fate of human Langerhans cells in hematopoietic stem cell transplantation.

Authors:  Matthew P Collin; Derek N J Hart; Graham H Jackson; Gordon Cook; James Cavet; Stephen Mackinnon; Peter G Middleton; Anne M Dickinson
Journal:  J Exp Med       Date:  2006-01-03       Impact factor: 14.307

10.  Identification of a radio-resistant and cycling dermal dendritic cell population in mice and men.

Authors:  Milena Bogunovic; Florent Ginhoux; Amy Wagers; Martine Loubeau; Luis M Isola; Lauren Lubrano; Vesna Najfeld; Robert G Phelps; Celia Grosskreutz; Eilleen Scigliano; Paul S Frenette; Miriam Merad
Journal:  J Exp Med       Date:  2006-11-20       Impact factor: 14.307

View more
  17 in total

1.  Alternative mechanisms that mediate graft-versus-host disease in allogeneic hematopoietic cell transplants.

Authors:  James W Young
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

Review 2.  Graft versus tumor effects and why people relapse.

Authors:  J H Frederik Falkenburg; Inge Jedema
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

3.  The immune reconstitution of the skin following sex-mismatched allogeneic haematopoietic stem cell transplant: a prospective case series utilizing fluorescence in situ hybridization and immunohistochemistry.

Authors:  C L Stewart; C M Cornejo; K A Wanat; I Sander; S Samimi; S Prouty; J Seykora; P Zhang; M Rosenbach; E J Kim; R G Micheletti
Journal:  Br J Dermatol       Date:  2018-01-08       Impact factor: 9.302

4.  STR typing of skin swabs from individuals after an allogeneic hematopoietic stem cell transplantation.

Authors:  Roland Reibke; Katja Anslinger; Dagmar von Máriássy; Mareike Verbeek; Britta Gätjens; Roberta Schiller
Journal:  Int J Legal Med       Date:  2022-06-03       Impact factor: 2.686

Review 5.  Regulation of macrophage development and function in peripheral tissues.

Authors:  Yonit Lavin; Arthur Mortha; Adeeb Rahman; Miriam Merad
Journal:  Nat Rev Immunol       Date:  2015-12       Impact factor: 53.106

Review 6.  Langerhans cell origin and regulation.

Authors:  Matthew Collin; Paul Milne
Journal:  Curr Opin Hematol       Date:  2016-01       Impact factor: 3.284

Review 7.  Cell(s) of Origin of Langerhans Cell Histiocytosis.

Authors:  Matthew Collin; Venetia Bigley; Kenneth L McClain; Carl E Allen
Journal:  Hematol Oncol Clin North Am       Date:  2015-08-20       Impact factor: 3.722

8.  CD1c+ blood dendritic cells have Langerhans cell potential.

Authors:  Paul Milne; Venetia Bigley; Merry Gunawan; Muzlifah Haniffa; Matthew Collin
Journal:  Blood       Date:  2014-10-28       Impact factor: 25.476

Review 9.  Monocytes, macrophages, dendritic cells and neutrophils: an update on lifespan kinetics in health and disease.

Authors:  Amit A Patel; Florent Ginhoux; Simon Yona
Journal:  Immunology       Date:  2021-03-15       Impact factor: 7.215

Review 10.  Ontogeny and polarization of macrophages in inflammation: blood monocytes versus tissue macrophages.

Authors:  Adwitia Dey; Joselyn Allen; Pamela A Hankey-Giblin
Journal:  Front Immunol       Date:  2015-01-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.